Lemzoparlimab, a Differentiated Anti-CD47 Antibody in Combination with Rituximab in Relapsed and Refractory Non-Hodgkin’s Lymphoma: Initial Clinical Results Poster presentation at the 2021 ASH meeting
A first-in-patient study of lemzoparlimab, a differentiated anti-CD47 antibody, in subjects with relapsed/refractory malignancy: initial monotherapy results Poster presentation at the 2020 SITC Meeting
TJC4, A Differentiated RBC Sparing Anti-CD47 Antibody for Anti-Cancer Therapy Poster presentation at the 2019 ASH meeting
A differentiated CD47 therapeutic antibody recognizing a novel epitope and sparing erythrocytes and platelets Poster presentation at the 2017 EACR meeting
The safety, pharmacokinetics (PK), pharmacodynamics (PD) and clinical efficacy of uliledlimab, a differentiated CD73 antibody, in combination with atezolizumab in patients with advanced cancer Poster presentation at the 2021 ASCO meeting
Inhibition of B7-H3 by Enoblituzumab Elicits Antitumor Immune Modulation in Both Innate and Adaptive Immunity Poster presentation at the 2022 AACR meeting
A Phase I/IIa, Open-label, Dose-Escalation and Dose Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TJ107 in Chinese Patients with Advanced Solid Tumors Poster presentation at the 2019 SITC meeting
TJ-CD4B (ABL111), a Claudin18.2-targeted 4-1BB tumor engager induces potent tumor-dependent immune response without dose-limiting toxicity in preclinical studies Poster presentation at the 2021 SITC meeting
Claudin 18.2 – 4-1BB bispecific antibody induced potent tumor inhibition through tumor-specific 4-1BB activation Poster presentation at the 2020 AACR meeting
Discovery of a novel Claudin6-4-1BB bispecific antibody with potent anti-tumor activity through conditional 4-1BB activation Poster presentation at the 2022 AACR meeting
A novel immunocytokine fusion protein combining tumor-targeting anti-CD47 antibody with GM-CSF cytokine for enhanced anti-tumor efficacy Poster presentation at the 2018 AACR meeting
A novel anti-tumor anti-PDL1-IL7 immunocytokine targeting lymphocytes Poster presentation at the 2019 SITC meeting
